Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1992 2
1993 1
1994 5
1995 3
1996 4
1997 3
1998 4
1999 8
2000 9
2001 9
2002 7
2003 6
2004 6
2005 7
2006 13
2007 8
2008 5
2009 11
2010 17
2011 18
2012 17
2013 12
2014 20
2015 10
2016 14
2017 8
2018 11
2019 12
2020 15
2021 7
2022 11
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis.
Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, Varthya SB. Singh S, et al. Osteoporos Int. 2022 Jan;33(1):1-12. doi: 10.1007/s00198-021-06095-y. Epub 2021 Aug 25. Osteoporos Int. 2022. PMID: 34432115 Free PMC article. Review.
Romosozumab decreased the incidence of vertebral, nonvertebral, and clinical fractures significantly. In addition, decreased incidence of falls and increased bone mineral density at lumbar spine, total hip, and femoral neck was observed. ...Romo …
Romosozumab decreased the incidence of vertebral, nonvertebral, and clinical fractures significantly. In addition, decreased incidenc …
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Leder BZ, et al. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. Lancet. 2015. PMID: 26144908 Free PMC article. Clinical Trial.
The DATA study showed that combined teriparatide and denosumab increased bone mineral density more than either drug alone. Discontinuing teriparatide and denosumab, however, results in rapidly declining bone mineral density. In this DATA-Switch study, …
The DATA study showed that combined teriparatide and denosumab increased bone mineral density more than either d …
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Neer RM, et al. N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904. N Engl J Med. 2001. PMID: 11346808 Free article. Clinical Trial.
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decre …
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density …
Romosozumab in postmenopausal women with low bone mineral density.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. McClung MR, et al. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1. N Engl J Med. 2014. PMID: 24382002 Free article. Clinical Trial.
Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparat …
Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 mo …
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. Czerwinski E, et al. J Bone Miner Res. 2022 Dec;37(12):2435-2442. doi: 10.1002/jbmr.4719. Epub 2022 Oct 18. J Bone Miner Res. 2022. PMID: 36190391 Free PMC article. Clinical Trial.
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo. ...Key secondary endpoints included BMD chang …
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and d …
Effects of lifelong testosterone exposure on health and disease using Mendelian randomization.
Mohammadi-Shemirani P, Chong M, Pigeyre M, Morton RW, Gerstein HC, Paré G. Mohammadi-Shemirani P, et al. Elife. 2020 Oct 16;9:e58914. doi: 10.7554/eLife.58914. Elife. 2020. PMID: 33063668 Free PMC article.
Lifelong increased free testosterone had beneficial effects on increased bone mineral density, and decreased body fat; adverse effects on decreased HDL, and increased risks of prostate cancer, androgenic alopecia, spinal stenosis, and hypertension; and …
Lifelong increased free testosterone had beneficial effects on increased bone mineral density, and decreased bod …
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. McClung MR, et al. J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22. J Bone Miner Res. 2018. PMID: 29694685 Free article. Clinical Trial.
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532). ...Percentage change from baseline in BMD and bone turnover marker …
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral …
History of risedronate.
McClung MR, Ebetino FH. McClung MR, et al. Bone. 2020 Aug;137:115407. doi: 10.1016/j.bone.2020.115407. Epub 2020 May 6. Bone. 2020. PMID: 32387834 Review.
Risedronate was shown to significantly reduce serum alkaline phosphatase and clinical features in patients with Paget's disease and was approved for this indication, at a dose of 30 mg daily for 2 months, in 1998. Formal dose response testing for treatment of osteoporosis …
Risedronate was shown to significantly reduce serum alkaline phosphatase and clinical features in patients with Paget's disease and w …
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC. Bone HG, et al. J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2. J Clin Endocrinol Metab. 2011. PMID: 21289258 Clinical Trial.
CONTEXT: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. ...DESIGN: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel- …
CONTEXT: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover marker …
Raloxifene.
Balfour JA, Goa KL. Balfour JA, et al. Drugs Aging. 1998 Apr;12(4):335-41; discussion 342. doi: 10.2165/00002512-199812040-00006. Drugs Aging. 1998. PMID: 9571395 Review.
Raloxifene inhibits bone resorption induced by estrogen deficiency in murine and human studies and lowers serum cholesterol levels. In clinical studies in postmenopausal women, raloxifene 60 mg/day for 2 years significantly increased bone mineral de …
Raloxifene inhibits bone resorption induced by estrogen deficiency in murine and human studies and lowers serum cholesterol levels. In cl …
260 results